Sionna Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(a) None.
(b) None.
(c)The following table describes, for the three months ended June 30, 2025, each trading arrangement under which any of our directors or executive officers adopted, modified, orterminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangements" as defined in Item 408(c) of Regulation S-K.
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Expiration Date of Trading Arrangement (1) | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Michael Cloonan (President and Chief Executive Officer) | Adoption (May 21, 2025) | Rule 10b5-1 trading arrangement | Sale | August 17, 2026 | Up to 200,000 |
| Elena Ridloff (Chief Financial Officer and Head of Corporate Development) | Adoption (May 20, 2025) | Rule 10b5-1 trading arrangement | Sale | August 6, 2026 | Up to 85,000 |
| Jennifer Fitzpatrick (Chief Legal Officer) | Adoption (June 5, 2025) | Rule 10b5-1 trading arrangement | Sale | September 15, 2026 | Up to 41,000 |
(1) A trading arrangement may expire on an earlier date if all contemplated transactions are completed before such trading arrangement's expiration date, upon termination by broker or the holder of the trading arrangement, or as otherwise provided in the trading arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.